Progressive Multifocal Leukoencephalopathy and Tysabri

Progressive multifocal leukoencephalopathy (PML) is linked to Tysabri, a drug manufactured by Biogen-Idec, used for the treatment of multiple sclerosis (MS). Although progressive multifocal leukoencephalopathy was once seen only in AIDS patients and in individuals whose immune systems are severely compromised by immunosuppressant drugs, progressive multifocal leukoencephalopathy has been documented in a number of people who were taking Tysabri (generic name, natalizumab) for their multiple sclerosis.

Tysabri Off the Market For Eighteen Months

In April 2009, Biogen-Idec reported that since Tysabri was reintroduced to the U.S. market in 2006, a sixth multiple sclerosis patient treated with Tysabri has developed progressive multifocal leukoencephalopathy. Tysabri had been taken off the market for a year and a half after three patients developed progressive multifocal leukoencephalopathy during clinical trials studying Tysabri.

In addition, in October 2008 a case of progressive multifocal leukoencephalopathy in a patient treated with Tysabri was confirmed. The individual had received 14 infusions of Tysabri (infusions of Tysabri are done once per month).

Monitoring Tysabri Patients for progressive multifocal leukoencephalopathy Symptoms

Roughly 40,000 people are using Tysabri in the United States, and Biogen-Idec recommends that every patient taking Tysabri be monitored very closely by their physicians for the early symptoms of progressive multifocal leukoencephalopathy, which include:

cognitive losses
memory loss
balance and coordination problems
visual changes
speech difficulties
unexplained fatigue and weakness

Biogen-Idec's "TOUCH Prescribing Program" is required of all patients; they must enroll in the program and be monitored for PML symptoms. Although Biogen-Idec had once announced a goal to provide Tysabri to 100,000 patients with multiple sclerosis by the end of 2010, it recently backed down from this goal. Even so, Tysabri made about $225 million in sales in a recent quarter for Biogen-Idec.

MS Treatment Options

Tysabri can be used either alone, as a "monotherapy,” for multiple sclerosis, or in conjunction with Avonex, another treatment for multiple sclerosis. However, the warning for Tysabri is the same no matter how it is used, which is as follows: “Tysabri increases an individual's risk of contracting progressive multifocal leukoencephalopathy.”

If you fear that a progressive multifocal leukoencephalopathy diagnosis for your loved one or yourself is linked to Tysabri, you may be eligible to seek compensation for your physical, emotional and financial losses. Contact our progressive multifocal leukoencephalopathy attorneys today to schedule a private, no-cost consultation in which we will determine your eligibility.

Online Lawyer Source

Lawyers & Legal News Near You

Need Legal Help?

Start Here for a Free Case Review!